Ludwig Maximillian University Munich, Department of Gynecology and Obstetrics
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Untch, Michael
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
40
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (

Active, not recruiting
2
11
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza
Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Breast Cancer
01/25
02/26
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Untch, Michael
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label

Recruiting
4
108
Europe
Ontruzant, SB3, Chemotherapy, Pertuzumab
Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd.
Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
04/23
07/23
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
40
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (

Active, not recruiting
2
11
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza
Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC
Malignant Neoplasm of Breast, Breast Cancer
01/25
02/26
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26

Download Options